33 / 43
Nivolumab vs Investigator’s Choice for Platinum-Refractory Recurrent or
Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck
(CheckMate 141): Outcomes in First-line R/M Patients and Updated Safety
and Efficacy
Maura L. Gillison,
1
George Blumenschein Jr.,
2
Jerome Fayette,
3
Joel Guigay,
4
A. Dimitrios Colevas,
5
Lisa Licitra,
6
Kevin J. Harrington,
7
Stefan Kasper,
8
Everett E. Vokes,
9
Caroline Even,
10
Francis Worden,
11
Nabil F. Saba,
12
Lara
Carmen Iglesias Docampo,
13
Robert Haddad,
14
Tamara Rordorf,
15
Naomi Kiyota,
16
Makoto Tahara,
17
Mark Lynch,
18
Justin Kopit,
18
Robert L. Ferris
19
ASCO 2017